Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-020-03677-4
Abstract: Objective In 2018, cIMPACT-NOW update 3 concluded that WHO grade II/III IDH-wildtype diffuse astrocytomas that contain TERT promoter mutations, chromosome 7 gain/10 loss, and/or EGFR amplification, correspond to a WHO grade IV diagnosis and should… read more here.
Keywords: diffuse astrocytic; institution; idh; idh wildtype ... See more keywords
p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors
Sign Up to like & getrecommendations! Published in 2017 at "Cellular Oncology"
DOI: 10.1007/s13402-017-0361-5
Abstract: PurposeDiffuse astrocytic tumors are the most frequently occurring primary central nervous system (CNS) tumors. Their histological sub-classification into diffuse astrocytoma (DA), anaplastic astrocytoma (AA) and glioblastoma (GB) is challenging and the available prognostic factors are… read more here.
Keywords: diffuse astrocytic; survivin; expression; p53 expression ... See more keywords
Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors
Sign Up to like & getrecommendations! Published in 2020 at "Neurologia medico-chirurgica"
DOI: 10.2176/nmc.oa.2019-0218
Abstract: Diffuse astrocytic and oligodendroglial tumors are frequently associated with symptomatic epilepsy, and predictive seizure control is important for the improvement of patient quality of life. To elucidate the factors related to drug resistance of brain… read more here.
Keywords: diffuse astrocytic; oligodendroglial tumors; seizure control; astrocytic oligodendroglial ... See more keywords